Equities Analysts Offer Predictions for BDX Q1 Earnings

Becton, Dickinson and Company (NYSE:BDX) – Investment analysts at Zacks Research increased their Q1 2025 earnings per share (EPS) estimates for Becton, Dickinson and Company in a report released on Thursday, November 28th. Zacks Research analyst R. Department now anticipates that the medical instruments supplier will earn $2.96 per share for the quarter, up from their previous forecast of $2.92. The consensus estimate for Becton, Dickinson and Company’s current full-year earnings is $14.43 per share. Zacks Research also issued estimates for Becton, Dickinson and Company’s Q2 2025 earnings at $3.45 EPS, Q3 2025 earnings at $3.73 EPS, Q4 2025 earnings at $4.29 EPS, FY2025 earnings at $14.43 EPS, Q1 2026 earnings at $3.18 EPS, Q2 2026 earnings at $3.84 EPS, Q3 2026 earnings at $4.02 EPS, Q4 2026 earnings at $4.52 EPS, FY2026 earnings at $15.57 EPS and FY2027 earnings at $16.75 EPS.

A number of other research firms also recently commented on BDX. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $255.00 to $275.00 in a research note on Tuesday, October 1st. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Finally, Evercore ISI upped their price objective on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $283.00.

Becton, Dickinson and Company Stock Down 0.0 %

Becton, Dickinson and Company stock opened at $221.90 on Monday. The company has a current ratio of 1.17, a quick ratio of 0.74 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $249.89. The company has a fifty day simple moving average of $234.16 and a 200 day simple moving average of $234.10. The company has a market cap of $64.14 billion, a P/E ratio of 37.36, a price-to-earnings-growth ratio of 1.65 and a beta of 0.43.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, topping analysts’ consensus estimates of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter in the prior year, the firm posted $3.42 EPS. The business’s revenue was up 6.9% on a year-over-year basis.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Peapack Gladstone Financial Corp lifted its holdings in Becton, Dickinson and Company by 2.1% during the 3rd quarter. Peapack Gladstone Financial Corp now owns 101,600 shares of the medical instruments supplier’s stock valued at $24,497,000 after purchasing an additional 2,057 shares during the last quarter. Synovus Financial Corp lifted its stake in shares of Becton, Dickinson and Company by 9.8% during the 3rd quarter. Synovus Financial Corp now owns 9,017 shares of the medical instruments supplier’s stock worth $2,174,000 after buying an additional 808 shares during the last quarter. Tidal Investments LLC boosted its holdings in shares of Becton, Dickinson and Company by 309.0% during the 3rd quarter. Tidal Investments LLC now owns 47,461 shares of the medical instruments supplier’s stock worth $11,443,000 after buying an additional 35,858 shares during the period. Wilmington Savings Fund Society FSB grew its stake in Becton, Dickinson and Company by 93.8% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 151,082 shares of the medical instruments supplier’s stock valued at $36,426,000 after buying an additional 73,108 shares during the last quarter. Finally, World Investment Advisors LLC raised its holdings in Becton, Dickinson and Company by 36.3% in the 3rd quarter. World Investment Advisors LLC now owns 13,943 shares of the medical instruments supplier’s stock valued at $3,362,000 after acquiring an additional 3,713 shares during the period. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th will be given a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.87%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. The ex-dividend date of this dividend is Monday, December 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 63.97%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.